Compare AbCellera Biologics Inc (ABCL) vs Nokia Corp (NOK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbCellera Biologics Inc vs Nokia Corp — how do they compare? AbCellera Biologics Inc trades at $9.23 (market cap $2.99B), while Nokia Corp trades at $10.27 (market cap $53.00B). The key difference: Nokia Corp is far larger — about 17.7× AbCellera Biologics Inc's market cap, and Nokia Corp pays a 1.73% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | NOK | |
|---|---|---|
Market Cap | $2.99B | $53.00B |
Sector | Health | Technology |
52-Week High | $9.76 | $16.83 |
52-Week Low | $2.78 | $4.13 |
Enterprise Value | $2.58B | $50.95B |
Dividend Yield | — | 1.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) surged 34.78% to $9.34, driven by positive Phase 2 trial results for its menopause drug ABCL635. Despite negative net income margins and cash burn, analyst consensus is strongly bullish with a $15.50 price target. The stock shows a bullish technical trend, with support at $8 and resistance at $10, though RSI levels indicate overbought conditions.
The outlook hinges on ABCL635's clinical progress and future revenue potential, but high valuation ratios and persistent losses pose significant risks. Investor sentiment is optimistic due to recent drug trial success, yet the company must demonstrate a path to profitability to justify current market enthusiasm.
Nokia (NOK) trades at $9.12, down 2.67% today amid a bearish technical signal, with mixed earnings performance including a Q2 2026 EPS beat. Revenue has stabilized near $20B annually, but net margins are thin at 3.47%. The company is pivoting toward AI and cloud infrastructure, with recent news highlighting demand growth in these areas. Cash flow turned negative in 2025, though the balance sheet remains solid with $8.91B in cash.
Outlook is cautiously optimistic due to AI-driven demand and insider buying, but risks include telecom spending volatility and high P/E valuation. Analyst consensus is bullish with 60% buy ratings. The stock faces near-term pressure from technical indicators but offers long-term potential if AI initiatives accelerate growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Nokia Corp
Nokia is a leading vendor in the telecommunications equipment industry. The company's network business derives revenue from selling wireless and fixed-line hardware, software, and services. Nokia's technology segment licenses its patent portfolio to handset manufacturers and makes royalties from Nokia-branded cellphones. The company, headquartered in Espoo, Finland, operates on a global scale, with most of its revenue from communication service providers.
Read more on NOK →
